Table 1.
Comparison of demographics and treatment between patients with MCD, FSGS, and MN.
| N | MCD | FSGS | MN | P-value |
|---|---|---|---|---|
| 3305 | 655 | 1424 | ||
| Age of onset (yrs) | 31 (16, 49) | 39 (19, 55) | 60 (49, 69) | < 0.001a,b,c |
| Age at renal biopsy (yrs)* | 34 (20, 50) | 41 (24, 58) | 61 (51, 70) | < 0.001a,b,c |
| Age of enrollment (yrs) | 42 (29, 56) | 47 (33, 62) | 67 (58, 74) | < 0.001a,b,c |
| Male, n (%) | 1899 (57.5%) | 378 (57.5%) | 911 (64.0%) | < 0.001b,c |
| Present treatment | ||||
| Oral PSL | 2881 (87.2%) | 530 (80.9%) | 1104 (77.5%) | < 0.001a,b |
| IV mPSL | 256 (7.7%) | 73 (11.1%) | 42 (2.9%) | < 0.001a,b,c |
| Cyclosporine | 1559 (47.2%) | 337 (51.5%) | 621 (43.6%) | 0.003c |
| Tacrolimus | 51 (1.5%) | 26 (4.0%) | 15 (1.1%) | < 0.001a,c |
| Cyclophosphamide | 16 (0.5%) | 3 (0.5%) | 20 (1.4%) | 0.002b |
| Mizoribine | 403 (12.2%) | 81 (12.4%) | 238 (16.7%) | < 0.001b,c |
| MMF | 86 (2.6%) | 29 (4.4%) | 1 (0.1%) | < 0.001a,b,c |
| Rituximab | 199 (6.0%) | 38 (5.8%) | 10 (0.7%) | < 0.001b,c |
| PSL + cyclosporine | 1395 (42.2%) | 299 (45.6%) | 525 (36.9%) | < 0.001b,c |
| Dosage of present treatment | ||||
| Oral PSL (mg/day) | 21.2 ± 17.8 | 20.0 ± 16.9 | 18.8 ± 15.4 | 0.001b |
| IV mPSL (mg/day) | 568.7 ± 316.5 | 557.5 ± 219.7 | 558.7 ± 241.9 | 0.993 |
| Cyclosporine (mg/day) | 97.0 ± 40.8 | 95.8 ± 42.4 | 93.7 ± 46.0 | 0.149 |
| Tacrolimus (mg/day) | 2.4 ± 1.0 | 3.3 ± 2.1 | 2.5 ± 0.6 | 0.099 |
| Cyclophosphamide (mg/day) | 76.6 ± 33.5 | 83.3 ± 57.7 | 65.0 ± 22.1 | 0.349 |
| Mizoribine (mg/day) | 150.8 ± 66.2 | 148.3 ± 68.4 | 138.0 ± 42.7 | 0.144 |
| MMF (mg/day) | 1459.3 ± 521.4 | 1456.9 ± 586.4 | 750 | 0.359 |
| Rituximab (mg/month) | 594.3 ± 407.5 | 811.2 ± 612.9 | 511.1 ± 33.3 | 0.112 |
| Steroid‑resistant NS | 213 (6.4%) | 236 (36.0%) | 540 (37.9%) | < 0.001a,b |
| SDNS or FRNS | 2320 (70.2%) | 265 (40.5%) | 351 (24.6%) | < 0.001a,b,c |
| Persistent proteinuria ≥ 0.5 g/gCr | 583 (17.6%) | 326 (49.8%) | 828 (58.1%) | < 0.001a,b,c |
Data are expressed as median (interquartile range), mean ± SD or number (percentage).
MCD minimal change disease, FSGS focal segmental glomerulosclerosis, MN membranous nephropathy, NS nephrotic syndrome, PSL prednisolone, mPSL methylprednisolone, MMF Mycophenolate mofetil, SDNS steroid-dependent nephrotic syndrome, FRNS frequently relapsing nephrotic syndrome.
aP < 0.05, MCD vs. FSGS, bP < 0.05, MCD vs. MN, cP < 0.05, FSGS vs. MN. Kruskal–Wallis tests with Bonferroni-corrected P-values.
*Number of missing values, n = 353 (10.7%) in MCD; n = 23 (3.5%) in FSGS; n = 40 (2.8%) in MN.